08-Jul-2026 16:53:19

SUVEN PHARMA RAISED RS 248.84 CR FUNDS FROM QIB @ ₹134/SHARE

• 1.85 Cr shares allotted at ₹134 per share for ₹248.84 Cr consideration from 17 non-promoter persons/entities. • Paid-up equity share capital increased to ₹282.56 Cr. • Board approved re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term from Jan 21, 2027. • Company to incorporate a wholly-owned subsidiary in Singapore.

Suven Life Sciences Limited

← Back to feed